<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01671904</url>
  </required_header>
  <id_info>
    <org_study_id>GO28440</org_study_id>
    <secondary_id>2012-002351-42</secondary_id>
    <nct_id>NCT01671904</nct_id>
  </id_info>
  <brief_title>A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Phase IB, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This multi-center, open-label, dose-finding study will evaluate the safety and
      pharmacokinetics of venetoclax (GDC-0199, ABT-199) administered in combination with
      bendamustine and rituximab (BR) (MabThera/Rituxan) or bendamustine and obinutuzumab (BG) to
      participants with relapsed/refractory or previously untreated CLL. The study will explore two
      schedules for drug administration, Schedule A (venetoclax introduced before other agents) and
      Schedule B (introduced after other agents). In addition, the study will explore two
      venetoclax combination regimens: venetoclax+BR and venetoclax + BG (the latter is optional).
      The study is comprised of two stages for each participant population: a dose-finding stage
      and a safety-expansion stage. The dose-finding stage will explore multiple doses of
      venetoclax to be used in combination with fixed doses of BR or BG.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2014</start_date>
  <completion_date type="Anticipated">June 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Schedule (Sch) A (Cycle [Cy] 1 Day [D] 1 to Cy1D21), Sch B (Cy1D21 to Cy2D28) (Cy length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Sch A (Cy1D1 to Cy1D21), Sch B (Cy1D21 to Cy2D28) (Cy length = 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Plasma): Minimum Plasma Concentration (Cmin) of Venetoclax</measure>
    <time_frame>Sch A: Prd (0 h) on D 1 of Week 1-5; prd (0 h) on D1 of Cy (1 Cy=28 day) 1,2,4,6 and on Cy1D3; Sch B: Prd (0 h) on D1 of Cy1,3,4,6; prd (0 h) on Cy1D22, D1, 8, 15, 22 of Cy2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Plasma): Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax</measure>
    <time_frame>Sch A: Prd (0 h), 8 h psd on D1 of Week 1-5; prd (0h) on D1 of Cy1,2,4,6, Cy1D3; 2,4,6,8h psd; Sch B: Prd (0h) on D1 of Cy1,2,3,4,6, Cy1D22, D8,15,22 of Cy2 (1 Cy=28 day); 8h psd on Cy1D22, D1,8,15,22 of Cy2; Cy3D1:2,4,6,8h psd</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Serum): Cmax of Rituximab</measure>
    <time_frame>Sch A and B: Prd (0 h), end of infusion (EOI) on D1 of Cy1, 2; prd (0 h) on D1 of Cy4, 6 and 4 weeks after Cy6D1; Prd (0 h) of Cy3D1 of Sch B (1 Cy=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Serum): Cmin of Rituximab</measure>
    <time_frame>Sch A and B: Prd (0 h), EOI on D1 of Cy1, 2; prd (0 h) on D1 of Cy4, 6 and 4 weeks after Cy6D1; Prd (0 h) of Cy3D1 of Sch B (1 Cy=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Serum): Cmax of Obinutuzumab</measure>
    <time_frame>Sch A: Prd (0 h), EOI on D1,2,8,15 of Cy1, Cy2D1; prd (0 h) on Cy1D3, Cy3D1, D1 of Cy4, 5, 6 and 4 weeks after Cy6D1; Sch B: Prd (0 h), EOI on D1,2,8,15 of Cy1, D1 of Cy2, 3, 4, 5, 6; Prd (0 h) of Cy1D22; 4 weeks after Cy6D1 (1 Cy=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Serum): Cmin of Obinutuzumab</measure>
    <time_frame>Sch A: Prd (0 h) on D1,2,8,15 of Cy1, D1 of Cy2, Cy1D3, Cy3D1, D1 of Cy4, 5, 6; Sch B: Prd (0 h) on D1,2,8,15 of Cy1, D1 of Cy2, 3, 4, 5, 6, on D22 of Cy1 (1 Cy=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Plasma): Cmax of Bendamustine</measure>
    <time_frame>Sch A: Prd (0 h), EOI on Cy1D2; Sch B: Prd (0 h), EOI on Cy1D2, Cy3D2 (1 Cy=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Plasma): Cmin of Bendamustine</measure>
    <time_frame>Sch A: Prd (0 h) on Cy1D2; Sch B: Prd (0 h) on Cy1D2, Cy3D2 (1 Cy=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Guidelines</measure>
    <time_frame>Baseline up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response According to IWCLL 2008 Guidelines</measure>
    <time_frame>Baseline up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Plasma): Area Under the Concentration-Time Curve (AUC) of Venetoclax</measure>
    <time_frame>Sch A:Predose (prd[0 h]), 8 hour (h) postdose (psd) on D1 of Week 1-5; prd(0h) on D1 of Cy1,2,4,6, Cy1D3; 2,4,6,8h psd; Sch B:Prd(0h) on D1 of Cy1,2,3,4,6, Cy1D22, D8,15,22 of Cy2 (1 Cy=28 day); 8h psd on Cy1D22, D1,8,15,22 of Cy2; Cy3D1:2,4,6,8h psd</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Plasma): Maximum Plasma Concentration (Cmax) of Venetoclax</measure>
    <time_frame>Sch A: Prd (0 h), 8 h psd on D1 of Week 1-5; prd (0h) on D1 of Cy1,2,4,6, Cy1D3; 2,4,6,8h psd; Sch B: Prd (0h) on D1 of Cy1,2,3,4,6, Cy1D22, D8,15,22 of Cy2 (1 Cy=28 day); 8h psd on Cy1D22, D1,8,15,22 of Cy2; Cy3D1:2,4,6,8h psd</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR, Assessed With the use of Computed tomography (CT) Scanning</measure>
    <time_frame>Baseline up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to IWCLL 2008 Guidelines</measure>
    <time_frame>Baseline up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in B-Cells</measure>
    <time_frame>Baseline up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in T-Cells</measure>
    <time_frame>Baseline up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Natural Killer (NK) Cells</measure>
    <time_frame>Baseline up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Immunoglobulin</measure>
    <time_frame>Baseline up to approximately 5.75 years</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Dose-Finding: Schedule A (Optional): CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional study arm: In four cohorts of participants with relapsed/refractory or previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before bendamustine and obinutuzumab. Schedule A will be explored prior to Schedule B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Finding: Schedule A: Previously Untreated CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In four cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and rituximab in the dose-finding stage. In Schedule A, venetoclax will be introduced before bendamustine and rituximab. Schedule A will be explored prior to Schedule B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Finding: Schedule A: Relapsed/Refractory CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In four cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and rituximab in the dose-finding stage. In Schedule A, venetoclax will be introduced before bendamustine and rituximab. Schedule A will be explored prior to Schedule B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Finding: Schedule B (Optional): CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional study arm: In four cohorts of participants with relapsed/refractory or previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after bendamustine and obinutuzumab. Schedule A will be explored prior to Schedule B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Finding: Schedule B: Previously Untreated CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In four cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and rituximab in the dose-finding stage. In Schedule B, venetoclax will be introduced after bendamustine and rituximab. Schedule A will be explored prior to Schedule B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Finding: Schedule B: Relapsed/Refractory CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In four cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose bendamustine and rituximab in the dose-finding stage. In Schedule B, venetoclax will be introduced after bendamustine and rituximab. Schedule A will be explored prior to Schedule B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Expansion (Optional): Previously Untreated CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with bendamustine and obinutuzumab in the safety expansion stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Expansion: Previously Untreated CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with bendamustine and rituximab in the safety expansion stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Expansion: Relapsed/Refractory CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with bendamustine and rituximab in the safety expansion stage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter [mg/m^2]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.</description>
    <arm_group_label>Dose-Finding: Schedule A (Optional): CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule A: Previously Untreated CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule A: Relapsed/Refractory CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule B (Optional): CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule B: Previously Untreated CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule B: Relapsed/Refractory CLL</arm_group_label>
    <arm_group_label>Safety Expansion (Optional): Previously Untreated CLL</arm_group_label>
    <arm_group_label>Safety Expansion: Previously Untreated CLL</arm_group_label>
    <arm_group_label>Safety Expansion: Relapsed/Refractory CLL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Participants will receive IV infusion of obinutuzumab (100 milligrams [mg]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.</description>
    <arm_group_label>Dose-Finding: Schedule A (Optional): CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule B (Optional): CLL</arm_group_label>
    <arm_group_label>Safety Expansion (Optional): Previously Untreated CLL</arm_group_label>
    <other_name>GA101; RO5072759</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Participants will receive IV infusion of rituximab (375 mg/m^2) on Day 1 of Cycle 1 and 500 mg/m^2 administered on Day 1 of Cycles 2-6.</description>
    <arm_group_label>Dose-Finding: Schedule A: Previously Untreated CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule A: Relapsed/Refractory CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule B: Previously Untreated CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule B: Relapsed/Refractory CLL</arm_group_label>
    <arm_group_label>Safety Expansion: Previously Untreated CLL</arm_group_label>
    <arm_group_label>Safety Expansion: Relapsed/Refractory CLL</arm_group_label>
    <other_name>MabThera; Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Participants will receive multiple doses of venetoclax orally once daily.</description>
    <arm_group_label>Dose-Finding: Schedule A (Optional): CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule A: Previously Untreated CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule A: Relapsed/Refractory CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule B (Optional): CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule B: Previously Untreated CLL</arm_group_label>
    <arm_group_label>Dose-Finding: Schedule B: Relapsed/Refractory CLL</arm_group_label>
    <arm_group_label>Safety Expansion (Optional): Previously Untreated CLL</arm_group_label>
    <arm_group_label>Safety Expansion: Previously Untreated CLL</arm_group_label>
    <arm_group_label>Safety Expansion: Relapsed/Refractory CLL</arm_group_label>
    <other_name>ABT-199; GDC-0199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of relapsing/refractory or previously untreated CLL

          -  Eastern Cooperative Oncology Group (ECOG) performance score of less than equal to
             (&lt;/=) 1

          -  Adequate bone marrow function

          -  Adequate coagulation, renal and hepatic function

          -  Hematological values within the limits independent of growth factor support or
             transfusion unless cytopenia is caused by the underlying disease, i.e., no evidence of
             additional bone marrow dysfunction (e.g., myelodysplastic syndrome, hypoplastic bone
             marrow)

        Exclusion Criteria:

          -  Participants received an allogeneic stem cell transplant

          -  Known human immunodeficiency virus (HIV) positivity

          -  Uncontrolled autoimmune hemolytic anemia or thrombocytopenia

          -  Positive test results for chronic hepatitis B infection and hepatitis C virus (HCV)

          -  Received any anti-cancer therapy including chemotherapy or radiotherapy, steroid
             therapy for anti-neoplastic intent, and investigational therapy, including targeted
             small molecule agents within 28 days prior to the first dose of study drug or has not
             recovered to less than Grade 2 clinically significant adverse effect(s)/toxicity(s) of
             the previous therapy

          -  Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic,
             immunologic, cardiovascular, or hepatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-5354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Hospital; Cancer Clinical Trials</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Hematology and Oncology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apotheke des Universitätsklinikums Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Koln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwabing</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtitätsklinikum Ulm; Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2012</study_first_submitted>
  <study_first_submitted_qc>August 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2012</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

